In the intervention strategy with cancer-prone Pten-null mice, in which progressive increase in MTA1 levels were associated with age-related aggressiveness of prostate cancer (Figure 1E), we found a substantial decrease in MTA1 levels in response to pterostilbene treatment at any ages examined by immunoblotting or IHC (Figure 6A and 6C and Supplementary Figure S4). Here, PTEN is linked to prostate cancer.